Last reviewed · How we verify
AC-203
AC-203 is a selective agonist of the kappa opioid receptor.
AC-203 is a selective agonist of the kappa opioid receptor. Used for Chronic pain.
At a glance
| Generic name | AC-203 |
|---|---|
| Sponsor | TWi Biotechnology, Inc. |
| Drug class | kappa opioid receptor agonist |
| Target | kappa opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | Phase 2 |
Mechanism of action
Activation of the kappa opioid receptor is thought to produce analgesia with a lower risk of respiratory depression compared to mu opioid receptor agonists. AC-203 has been investigated for its potential to treat pain in various conditions.
Approved indications
- Chronic pain
Common side effects
- Nausea
- Vomiting
- Dizziness
Key clinical trials
- An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS) (PHASE2, PHASE3)
- A Proof-of-Concept Study of Topical AC-203 in Patients With Bullous Pemphigoid (PHASE2)
- A Double-blind, Intra-individual Comparison, POC Trial of AC-203 in EB Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |